A common misconception of Lung Cancer is that it’s just a smoker’s disease. Whilst smoking is a leading cause, non-smokers can also develop lung cancer due to factors like air pollution, genetic predisposition, and second-hand smoke. This Lung Cancer Awareness Month we encourage you to familiarise yourself with the main signs and symptoms of this…
The PECATI trial, presented at ESMO 2024, brings promising news for patients with advanced B3 thymoma and thymic carcinoma, rare types of cancer originating in the thymus gland. This study evaluated the combination of two drugs, lenvatinib and pembrolizumab, in patients who had already undergone other treatments and did not have autoimmune disorders. In the…
The 5th International Meeting on Lung Cancer was a highly successful event, bringing together leading experts and clinicians to discuss the latest advancements in lung cancer treatment. Dr. Papadatos-Pastos, serving as a member of both the organizing and scientific committees, played a crucial role in shaping the program, which featured distinguished speakers from the US,…
Resources for physicians: Discussing Antibody Drug Conjugates in NSCLCResources for physicians: Dr Papadatos-Pastos presentation on Antibody Drug Conjugates https://www.vumedi.com/video/advances-in-adcs-for-the-treatment-of-nsclc/ Requires registration in vumedi
Resources for physicians: Dr Papadatos-Pastos presentation on 1st line treatment for EGFR driven non small cell lung cancer https://www.vumedi.com/video/optimizing-treatment-intensification-in-1l-egfr-mutated-nsclc/ Requires registration in vumedi
Hopeful horizons for lung cancer patients As seen in the Evening Standard newspaper on September 10, 2024 The article in text format: Hopeful horizons for lung cancer patients Lung cancer treatment has made great strides in recent years, offering patients more effective options and better outcomes. Traditional treatments like surgery, chemotherapy and radiation are still…
The MARS2 trial (Mesothelioma and Radical Surgery 2) was designed to evaluate the effectiveness of pleurectomy/decortication (P/D) surgery in patients with malignant pleural mesothelioma, a rare and aggressive cancer caused by asbestos exposure. The trial aimed to determine whether this surgery, which removes the lining of the lung and potentially other affected tissues, improves survival…
Lung cancer remains one of the most common and lethal cancers worldwide, but advances in molecular diagnostics have led to the identification of specific aberrations driving the disease. One such aberrations (rearrangement) occurs in the ROS1 gene, found in approximately 1-2% of patients with non-small cell lung cancer (NSCLC). Patients with ROS1-positive lung cancer tend…
Anaplastic Lymphoma Kinase (ALK)-driven non-small cell lung cancer (NSCLC) is a subtype of lung cancer caused by a genetic mutation in the ALK gene. This mutation leads to abnormal protein production, causing cancer cells to grow uncontrollably. ALK mutations are found in about 5% of NSCLC cases and are more common in younger people and…
Lung cancer is one of the most common and deadliest cancers worldwide, and about 85% of all lung cancers are a type known as non-small cell lung cancer (NSCLC). Among NSCLC patients, some have a specific genetic mutation in the EGFR gene, which stands for epidermal growth factor receptor. This mutation makes the cancer grow…
- 1
- 2